Samsung Biologics Co Ltd (207940) — Capital Reinvestment Ratio
Samsung Biologics Co Ltd (207940) has a Capital Reinvestment Ratio of 0.16x as of June 2026, meaning it reinvests 0% of its operating cash flow (₩624.80 Billion) in capital expenditures (₩99.08 Billion). Check Samsung Biologics Co Ltd tangible book value ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Samsung Biologics Co Ltd Capital Reinvestment Ratio (2017–2025)
This chart tracks Samsung Biologics Co Ltd's Capital Reinvestment Ratio across 8 annual periods. For the full cash flow conversion analysis, see 207940 operating cash flow.
Annual Capital Reinvestment Ratio for Samsung Biologics Co Ltd (2017–2025)
Year-by-year Capital Reinvestment Ratio for Samsung Biologics Co Ltd from 2017 to 2025. See Samsung Biologics Co Ltd free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.66x | ₩2.25 Trillion | ₩1.48 Trillion | ▼ -21.0% |
| 2024 | 0.83x | ₩1.66 Trillion | ₩1.38 Trillion | ▲ +25.2% |
| 2023 | 0.66x | ₩1.67 Trillion | ₩1.11 Trillion | ▼ -33.9% |
| 2022 | 1.00x | ₩953.05 Billion | ₩956.84 Billion | ▲ +12.3% |
| 2021 | 0.89x | ₩454.60 Billion | ₩406.25 Billion | ▲ +29.3% |
| 2020 | 0.69x | ₩202.09 Billion | ₩139.66 Billion | ▼ -96.4% |
| 2019 | 18.99x | ₩10.15 Billion | ₩192.84 Billion | ▲ +475.8% |
| 2017 | 3.30x | ₩149.82 Billion | ₩494.12 Billion | — |